Reslizumab
RES-38072
Phase 3 mab completed
Quick answer
Reslizumab for Severe Persistent Asthma is a Phase 3 program (mab) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Severe Persistent Asthma
- Phase
- Phase 3
- Modality
- mab
- Status
- completed